Oral Lorazepam (Ativan) Dosing in Adults
For anxiety or agitation, start with lorazepam 0.5-1 mg orally 2-4 times daily as needed, with a maximum of 4 mg in 24 hours; reduce to 0.25-0.5 mg in elderly or debilitated patients with a maximum of 2 mg in 24 hours. 1
Standard Dosing by Indication
Anxiety and Agitation
- Initial dose: 0.5-1 mg orally 4 times daily as required 1
- Maximum daily dose: 4 mg in 24 hours 1
- Elderly/debilitated patients: 0.25-0.5 mg with maximum 2 mg in 24 hours 1
- Oral tablets can be used sublingually (off-label) 1
Insomnia
- Lorazepam may be considered when duration of action is appropriate for the patient's presentation 2
- Typical dosing: 1-4 mg at bedtime 3
- Lower doses recommended in elderly patients 2
Alcohol Withdrawal Syndrome
- Standard regimen: 1-4 mg orally/IV/IM every 4-8 hours 4
- Lorazepam is specifically recommended for patients with severe AWS, advanced age, recent head trauma, liver failure, respiratory failure, or other serious medical comorbidities 4
- Dosage started at 6-12 mg/day and tapered following resolution of withdrawal symptoms 4
Delirium Management (Cancer Patients)
- Initial dose: 1 mg subcutaneously or intravenously (maximum 2 mg) 5
- Lower doses (0.25-0.5 mg) in older/frail patients, those with COPD, or when co-administered with antipsychotics 5
- Can also be given orally or sublingually 5
Anticipatory Nausea/Vomiting (Chemotherapy)
- Alprazolam dosing (similar benzodiazepine): 0.25-0.5 mg orally 3 times daily, beginning night before treatment 6
- Elderly patients: 0.25 mg orally 2-3 times daily 6
Pharmacokinetic Considerations
Absorption and Onset
- Peak plasma concentrations: Reached within 2-3 hours after oral administration 7, 8, 9
- Bioavailability: Completely and rapidly absorbed orally 7
- Dose-proportional: 4 mg dose provides approximately 48 ng/mL peak concentration 7
Duration and Half-Life
- Elimination half-life: 14±5 hours (range 8.4-23.9 hours) 7, 8
- Duration of effects: 6-8 hours for intended therapeutic effects 7
- Time to steady-state: 2-3 days with multiple dosing 10, 9, 11
Metabolism
- Primary pathway: Glucuronide conjugation in liver 7
- Protein binding: 91±2% bound to plasma proteins 7
- Renal elimination: 74% excreted as lorazepam glucuronide in urine 7
Special Populations
Elderly Patients
- Reduced clearance: 20% decrease in total body clearance compared to younger adults 7
- Dosing adjustment: Use 0.25-0.5 mg doses with maximum 2 mg daily 1
- Increased sensitivity to CNS-depressant effects 2
Hepatic Impairment
- No dosage adjustment needed for hepatic disease alone, as lorazepam does not undergo cytochrome oxidation 7
- However, caution advised with signs of hepatic failure 2
Renal Impairment
- Volume of distribution: 40% higher in renally impaired patients 7
- Half-life: 25% longer in renal impairment, 75% longer in hemodialysis patients 7
- Dosing consideration: While lorazepam clearance unchanged, monitor for prolonged effects 7
Drug Interactions Requiring Dose Adjustment
Valproate Co-administration
- Reduce lorazepam dose by 50% when co-administered with valproate 7
- Valproate decreases lorazepam clearance by 40% and glucuronide formation by 55% 7
- Results in approximately 2-fold higher lorazepam concentrations 7
Oral Contraceptives
- May need to increase lorazepam dose in women taking oral contraceptives 7
- Oral contraceptives increase lorazepam clearance by 3.7-fold 7
- Results in 55% decrease in half-life and 50% increase in volume of distribution 7
Probenecid Co-administration
- Reduce lorazepam dose by 50% when co-administered with probenecid 7
- Probenecid prolongs lorazepam half-life by 130% and decreases clearance by 45% 7
CNS Depressants and Opioids
- Use extreme caution with concomitant opioids due to respiratory depression risk 7
- Additive CNS depression with alcohol, phenothiazines, barbiturates, MAO inhibitors 7
- Monitor closely for respiratory depression and sedation 7
Critical Safety Considerations
Tolerance and Dependence
- Regular use can lead to tolerance, addiction, and cognitive impairment 3
- Paradoxical agitation occurs in approximately 10% of patients 3
- Withdrawal symptoms can occur with rapid dose decrease or abrupt discontinuation 2
- Gradual tapering recommended when discontinuing after maintenance treatment 12
Contraindications and Cautions
- Avoid in pregnancy/nursing unless benefits outweigh risks 2, 7
- Caution with respiratory compromise: COPD, asthma, sleep apnea 2, 5
- Monitor for neonatal sedation/withdrawal if used late in pregnancy 7
- Not recommended during pregnancy or nursing per general guidelines 2
Administration Recommendations
- Take on empty stomach to maximize effectiveness 2
- Avoid alcohol and other CNS depressants 2, 7
- Allow appropriate sleep time and use only prescribed doses 2
- Downward dosage adjustment advised in elderly 2
Maintenance and Discontinuation
Long-term Use
- Steady-state levels: Directly proportional to daily dose, maintained after months of treatment 10, 9
- At 6 mg/day: mean steady-state level 88 ng/mL 10
- At 10 mg/day: mean steady-state level 164 ng/mL 10